CliffBio
small molecule

DEXTROMETHORPHAN POLISTIREX

DEXTROMETHORPHAN POLISTIREX

Loss of exclusivity—loss of exclusivity
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEXTROMETHORPHAN POLISTIREX
Active ingredientDEXTROMETHORPHAN POLISTIREX
StrengthEQ 30MG HYDROBROMIDE/5ML
Dosage formSUSPENSION, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2012
Marketing statusOTC

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DEXTROMETHORPHAN POLISTIREX patent cliff — loss of exclusivity — | CliffBio